Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.

In pharma's AI transformation, the technology was never the hard part — fixing the operating model that has to act on what AI ...

Pharmaceutical reshoring is constrained by supplier qualification, process validation, FDA compliance readiness, workforce ...

Lewis W. Coopersmith is an associate professor at Rider University and vice-president of Health Products Research.

Heidi Overton, a UNM-trained physician with Johns Hopkins general surgery training, was selected for FDA commissioner after ...

How drug pricing, tariffs, and manufacturing decisions are becoming connected. For years, pharmaceutical companies could ...

Spherix's VP of market access discusses how the IRA's maximum fair price is reshaping payer strategy, formulary design, and patient out-of-pocket costs far beyond negotiated drugs.

Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...

Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the ...

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...

The 340B spread mechanism permits covered entities to retain the difference between discounted acquisition cost and commercial or Medicare reimbursement, incentivizing revenue capture rather than ...

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...